Our results showed that compared to the control group, MZ-1 or doxycycline alone decreased the tumor size (Fig. 4h) and consequently prolonged mouse survival (Fig. 4i); and that dual targeting of MYC and JUNB by MZ-1 and doxycycline, respectively, significantly enhanced their anti-MM activity (Fig. 4g–i). Here, JUNB is linked to neoplasm.